Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action

Figure 4

Success rate based on mechanism of action. The clinical trial success rates were further analyzed based on the mechanism of action of the drug compound. The four categories, immunotherapy, host inhibitors, viral inhibitors, and other, were compared against the industry expectation for the transition probability of that drug class. The cumulative pass rate indicates the overall probability that a drug from that class will be successful in all phases and achieve FDA approval.